Education
About Us
Working with TipRanks
Follow Us
Marizyme Incorporated (MRZM)
OTHER OTC:MRZM
MRZM Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $0.10
Previous CloseN/A
Volume435.00
Average Volume (3M)0.00
Market Cap
$39.54K
Enterprise Value$26.63M
Total Cash (Recent Filing)$63.73K
Total Debt (Recent Filing)$26.66M
Price to Earnings (P/E)―
Beta9.63
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding131,793,090
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.01
Enterprise Value/Market Cap673.63
Enterprise Value/Revenue15.27
Enterprise Value/Gross Profit-51.56
Enterprise Value/Ebitda-0.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Marizyme News
PremiumCompany Announcements
Marizyme Inc. Wins FDA Nod for DuraGraft Storage Advancement
PremiumCompany Announcements
Marizyme Announces Director Julie Kampf’s ResignationMRZM FAQ
What was Marizyme Incorporated’s price range in the past 12 months?
Marizyme Incorporated lowest stock price was <$0.01 and its highest was $0.10 in the past 12 months.
What is Marizyme Incorporated’s market cap?
Marizyme Incorporated’s market cap is $39.54K.
When is Marizyme Incorporated’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Marizyme Incorporated’s earnings last quarter?
Marizyme Incorporated released its earnings results on Dec 23, 2021. The company reported -$0.045 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.045.
Is Marizyme Incorporated overvalued?
According to Wall Street analysts Marizyme Incorporated’s price is currently Overvalued.
Does Marizyme Incorporated pay dividends?
Marizyme Incorporated does not currently pay dividends.
What is Marizyme Incorporated’s EPS estimate?
Marizyme Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marizyme Incorporated have?
Marizyme Incorporated has 131,793,090 shares outstanding.
What happened to Marizyme Incorporated’s price movement after its last earnings report?
Marizyme Incorporated reported an EPS of -$0.045 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Marizyme Incorporated?
Currently, no hedge funds are holding shares in MRZM
Company Description
Marizyme Incorporated
Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. It offers DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. The company also develops various products using its Krillase protease-based therapeutic platform for treating complex wounds and burns, acute ischemic stroke, deep vein thrombosis, and dissolving plaque and biofilms on teeth. In addition, it focuses on developing products to mitigate the effects of ischemia reperfusion injury in other grafting and transplantation surgeries, and other indications. Further, it is involved in developing MATLOC, a point-of-care, lab-on-chip digital screening and diagnostic device platform for chronic kidney disease assessment. The company was formerly known as GBS Enterprises Incorporated. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida.
Technical Analysis
TNF Pharmaceuticals
―
Windtree Therapeutics
―
Vincerx Pharma Inc
―
Universe Pharmaceuticals
―
iSpecimen
―